The birth of AstraZeneca in 1999 marked a significant milestone in pharmaceutical history, uniting Swedish Astra AB with Britain’s Zeneca Group. While Astra AB’s roots traced back to 1913 in Södertälje, where medical professionals joined forces to establish the company, Zeneca emerged in 1993 when Imperial Chemical Industries split its pharmaceutical wing.
The merged entity has since grown into a global healthcare powerhouse. Through strategic acquisitions like Cambridge Antibody Technology and MedImmune in the mid-2000s, AstraZeneca has strengthened its research capabilities and drug development portfolio. The company now stands as a major player in the pharmaceutical industry, with its shares actively traded on the London Stock Exchange.
AstraZeneca (AZN) had two stock splits: a 3:1 split in April 1998 and a 2:1 split in July 2015. One share before 1998 equals six shares today.
Key Takeaways:
- Projected growth from $90 in 2025 to $2100 in 2050 suggests strong market dominance..
- AstraZeneca’s oncology and rare disease portfolios may drive significant value expansion through 2050.
- AstraZeneca’s stock price is projected to experience significant appreciation over the coming decades.
AstraZeneca Company Profile
| Country | United Kingdom |
| Ticker Symbol | AZN |
| Exchange | NASDAQ |
| Founded | 1999 |
| IPO Date | 1993 |
| Industry | Drug Manufacturers – General |
| Sector | Healthcare |
| Employees | 89,900 |
| CEO | Pascal Soriot |
| Website | astrazeneca |
AstraZeneca Fundamental & Technical Data
Fundamental Data: (Data Source: marketwatch.com)
| Metric | Value |
|---|---|
| 52 Week Range | 60.47 – 87.68 |
| Market Cap | $203.39B |
| Shares Outstanding | 3.1B |
| Public Float | 3.1B |
| Beta | 0.54 |
| P/E Ratio | 31.54 |
| EPS | $2.08 |
| Yield | 2.22% |
| Dividend | $0.50 |
| Ex-Dividend Date | Aug 9, 2024 |
| Short Interest | 4.63M (10/31/24) |
| % of Float Shorted | 0.15% |
| Average Volume | 5.33M |
Technical Data: (Data Source: stockanalysis.com)
| Metric | Value |
|---|---|
| Beta (5Y) | 0.18 |
| 52-Week Price Change | +2.10% |
| 50-Day Moving Average | 73.44 |
| 200-Day Moving Average | 74.70 |
| Relative Strength Index (RSI) | 37.08 |
| Average Volume (20 Days) | 8,612,893 |
Fundamentals: The stock shows moderate valuation with a P/E of 31.54 and steady dividend yield of 2.22%. The large market cap of $203.39B indicates a well-established company with stable operations.
Technical Analysis: Currently trading below both 50-day (73.44) and 200-day (74.70) moving averages. RSI at 37.08 suggests approaching oversold territory. Price movement shows modest yearly gain of 2.10%.
Market Sentiment: Low short interest (0.15%) indicates minimal bearish sentiment. Above-average trading volume suggests increased investor activity. Beta of 0.54 shows lower volatility compared to broader market.
AstraZeneca Stock Price Prediction Tomorrow
The stock is showing a bearish trend with a recent sharp decline, currently trading at $65.63. The stock has formed a clear downtrend pattern with decreasing price levels and higher trading volumes on down days. The price action suggests continued downward pressure in the immediate term. Technical indicators point to potential support around the $65 level, but momentum remains negative. Tomorrow’s trading could see the stock testing lower levels, possibly reaching $64.50-$65.00 range, unless there’s a significant positive catalyst.
AstraZeneca Stock Price Prediction Next Week
Looking at the weekly perspective, AstraZeneca’s stock has been in a consistent downtrend since September. The lack of strong buying pressure and declining volume profile suggests weakness could persist. However, the stock appears oversold on multiple timeframes, which could lead to a technical bounce. Key resistance levels lie around $67-68, while support exists at $64. For next week, the stock might consolidate in the $64-$66 range before potentially finding a bottom.
Where Will AstraZeneca Stock Be In 1, 3, 5, 7 and 10 years?
AstraZeneca’s stock shows significant growth potential over the next decade. In one year, the stock is expected to trade between $71 and $90, with an average price of $75. By year three, the range expands to $95-$135, averaging $100. The five-year outlook suggests a range of $135-$180, with a $155 average. Seven years out, the stock could reach $195-$245, averaging $220. The ten-year projection is most bullish, with prices ranging from $305-$370 and an average of $335.
| Timeframe | Low Price | Average Price | High Price |
|---|---|---|---|
| 1 Year | $71 | $75 | $90 |
| 3 Years | $95 | $100 | $135 |
| 5 Years | $135 | $155 | $180 |
| 7 Years | $195 | $220 | $245 |
| 10 Years | $305 | $335 | $370 |
AstraZeneca Stock Price Predication 2025
By 2025, AZN is expected to reach $90. AstraZeneca (AZN) market cap is expected to reach $300 billion and RSI may range between 50-60. Our analysts suggest the oncology portfolio expansion, particularly Calquence and Enhertu, might drive market confidence. The support level could establish at $70, while resistance might test $90. The potential breakthrough developments in Imfinzi cancer treatments may attract new institutional investors. This represents a potential annual increase of 8.5%.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2025 | $71 | $75 | $90 |
| Month (2025) | Low Price | High Price |
|---|---|---|
| January | $71 | $75 |
| February | $72 | $77 |
| March | $73 | $80 |
| April | $74 | $82 |
| May | $75 | $83 |
| June | $76 | $84 |
| July | $77 | $85 |
| August | $78 | $86 |
| September | $79 | $87 |
| October | $80 | $88 |
| November | $81 | $89 |
| December | $82 | $90 |
Read more forecast: Thermo Fisher Scientific (TMO) Stock Price Prediction
AstraZeneca Stock Price Predication 2026
By 2026, AZN is expected to reach $110. Following a projected 9.2% annual growth, the cardiovascular division could see major advancements through Brilinta and Crestor market expansion in developing regions. Support level might form at $80, with resistance potentially testing $110. New clinical data from Atacand studies would possibly influence market sentiment.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2026 | $80 | $85 | $110 |
| Month (2026) | Low Price | High Price |
|---|---|---|
| January | $82 | $91 |
| February | $83 | $93 |
| March | $84 | $95 |
| April | $85 | $98 |
| May | $86 | $100 |
| June | $87 | $102 |
| July | $88 | $104 |
| August | $89 | $106 |
| September | $90 | $107 |
| October | $91 | $108 |
| November | $92 | $109 |
| December | $93 | $110 |
AstraZeneca Stock Price Predication 2027
By 2027, AZN is expected to reach $135. With a projected 8.7% annual increase, the respiratory medicine portfolio might see significant expansion as Breztri Aerosphere and Bevespi Aerosphere could penetrate new markets. Technical patterns suggest support forming near $95, with resistance potentially extending to $135. Our analysts anticipate early-stage clinical results from Symbicort next-generation formulations may create positive market sentiment.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2027 | $95 | $100 | $135 |
| Month (2027) | Low Price | High Price |
|---|---|---|
| January | $95 | $112 |
| February | $96 | $115 |
| March | $97 | $118 |
| April | $98 | $121 |
| May | $99 | $124 |
| June | $100 | $127 |
| July | $101 | $129 |
| August | $102 | $131 |
| September | $103 | $132 |
| October | $104 | $133 |
| November | $105 | $134 |
| December | $106 | $135 |
AstraZeneca Stock Price Predication 2028
By 2028, AZN is expected to reach $155. A projected 7.8% growth might be fueled by expansion in rare disease treatments, particularly Soliris and Ultomiris. The support level could settle around $110, while resistance may test $155. Our analysts suggest potential breakthrough designations for new indications of Kanuma would possibly drive investor interest.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2028 | $110 | $125 | $155 |
| Month (2028) | Low Price | High Price |
|---|---|---|
| January | $110 | $138 |
| February | $112 | $141 |
| March | $114 | $143 |
| April | $116 | $145 |
| May | $118 | $147 |
| June | $120 | $149 |
| July | $122 | $151 |
| August | $124 | $152 |
| September | $126 | $153 |
| October | $128 | $154 |
| November | $129 | $155 |
| December | $130 | $155 |
AstraZeneca Stock Price Predication 2029
By 2029, AZN is expected to reach $180. With a projected 8.3% annual growth, the vaccine portfolio including Fluenz Tetra and FluMist Quadrivalent might capture larger market share. Support level could form at $135, with resistance potentially reaching $180. Market sentiment may strengthen as Evusheld demonstrates efficacy in new viral variants.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2029 | $135 | $155 | $180 |
| Month (2029) | Low Price | High Price |
|---|---|---|
| January | $135 | $160 |
| February | $138 | $163 |
| March | $141 | $166 |
| April | $144 | $169 |
| May | $147 | $171 |
| June | $150 | $173 |
| July | $153 | $175 |
| August | $156 | $176 |
| September | $159 | $177 |
| October | $162 | $178 |
| November | $164 | $179 |
| December | $165 | $180 |
AstraZeneca Stock Price Predication 2030
By 2030, AZN is expected to reach $210. Building on a projected 8.9% annual increase, major advancements in the cardiovascular and metabolism segment, particularly through new formulations of Bydureon and Brilinta, might reshape revenue forecasts. Support level could establish at $165, while resistance may extend to $210.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2030 | $165 | $185 | $210 |
| Month (2030) | Low Price | High Price |
|---|---|---|
| January | $165 | $185 |
| February | $168 | $189 |
| March | $171 | $193 |
| April | $174 | $196 |
| May | $177 | $199 |
| June | $180 | $202 |
| July | $183 | $204 |
| August | $186 | $206 |
| September | $189 | $207 |
| October | $192 | $208 |
| November | $194 | $209 |
| December | $195 | $210 |
Read more forecast: Xcel Energy Inc. (XEL) Stock Price Prediction
AstraZeneca Stock Price Predication 2031
By 2031, AZN is expected to reach $245. A projected 8.2% growth might be driven by the oncology portfolio expansion, as Lynparza and Tagrisso could receive breakthrough designations for additional cancer types. Support level might establish at $195, while resistance could test $245.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2031 | $195 | $220 | $245 |
AstraZeneca Stock Price Predication 2032
By 2032, AZN is expected to reach $285. With a projected 7.9% increase, respiratory medicines like Symbicort and Breztri Aerosphere might capture significant market share in emerging economies. Support level could form at $230, with resistance possibly reaching $285.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2032 | $230 | $255 | $285 |
AstraZeneca Stock Price Predication 2033
By 2033, AZN is expected to reach $325. Following a projected 8.5% growth, the rare disease portfolio, particularly Strensiq and Ultomiris, might expand into new therapeutic areas. Support level could settle at $265, while resistance may test $325.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2033 | $265 | $295 | $325 |
AstraZeneca Stock Price Predication 2034
By 2034, AZN is expected to reach $370. A projected 8.1% increase could be supported by advancements in the cardiovascular division, with Brilinta and Andexxa potentially gaining market share. Support level might form at $305, with resistance possibly extending to $370.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2034 | $305 | $335 | $370 |
AstraZeneca Stock Price Predication 2035
By 2035, AZN is expected to reach $420. With a projected 7.8% growth, the immunology portfolio including new formulations may reshape treatment paradigms. Support level could establish at $350, while resistance might test $420.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2035 | $350 | $385 | $420 |
AstraZeneca Stock Price Predication 2036
By 2036, AZN is expected to reach $475. A projected 8.3% increase might be driven by advancements in Evusheld and preventive medicine platforms. Support level could form at $395, while resistance may extend to $475. Our analysts suggest potential breakthroughs in vaccine technology would possibly enhance market valuation.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2036 | $395 | $435 | $475 |
AstraZeneca Stock Price Predication 2037
By 2037, AZN is expected to reach $535. Building on a projected 7.9% growth, the expansion of Calquence and Enhertu into multiple cancer indications might drive market momentum. Support level could establish at $445, while resistance may test $535. Market sentiment could strengthen with potential breakthrough designations in precision oncology.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2037 | $445 | $490 | $535 |
AstraZeneca Stock Price Predication 2038
By 2038, AZN is expected to reach $600. With a projected 8.7% increase, significant advancements in Soliris and Kanuma rare disease treatments might reshape revenue forecasts. Support level could form at $495, with resistance possibly reaching $600. Our analysts anticipate potential expansion in genetic medicine platforms.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2038 | $495 | $545 | $600 |
AstraZeneca Stock Price Predication 2039
By 2039, AZN is expected to reach $670. A projected 8.2% growth might be fueled by breakthroughs in Imfinzi immunotherapy combinations and expanded indications for Lynparza. Support level could establish at $550, while resistance may test $670. The development of novel biological therapies may drive institutional interest.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2039 | $550 | $610 | $670 |
AstraZeneca Stock Price Predication 2040
By 2040, AZN is expected to reach $750. With a projected 8.5% growth, advancements in personalized medicine through Orpathys and next-generation targeted therapies might transform treatment paradigms. Support level could establish at $615, while resistance may test $750. Our analysts anticipate breakthrough innovations in artificial intelligence-driven drug development may strengthen market position.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2040 | $615 | $680 | $750 |
| Month (2040) | Low Price | High Price |
|---|---|---|
| January | $615 | $685 |
| February | $620 | $695 |
| March | $625 | $705 |
| April | $630 | $715 |
| May | $635 | $720 |
| June | $645 | $725 |
| July | $655 | $730 |
| August | $665 | $735 |
| September | $675 | $740 |
| October | $685 | $745 |
| November | $695 | $748 |
| December | $700 | $750 |
Read more forecast: The Graph (GRT) Price Prediction
AstraZeneca Stock Price Predication 2050
By 2050, AZN is expected to reach $2100. Following a projected 9.1% compound annual growth rate from 2040, revolutionary breakthroughs in Lumoxiti and Koselugo platforms might redefine precision medicine. Support level could form at $1750, with resistance possibly extending to $2100. Our analysts suggest the integration of quantum computing in drug discovery and development would possibly catalyze unprecedented market valuation.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2050 | $1750 | $1925 | $2100 |
| Month (2050) | Low Price | High Price |
|---|---|---|
| January | $1750 | $1850 |
| February | $1775 | $1880 |
| March | $1800 | $1910 |
| April | $1825 | $1940 |
| May | $1850 | $1970 |
| June | $1875 | $2000 |
| July | $1900 | $2025 |
| August | $1925 | $2050 |
| September | $1950 | $2070 |
| October | $1975 | $2080 |
| November | $2000 | $2090 |
| December | $2025 | $2100 |
Who are the major competitors of AstraZeneca
| Company Name | Market Cap (USD) | Enterprise Value (USD) | Dividend % | YTD Return |
|---|---|---|---|---|
| AstraZeneca PLC (AZN) | 203.17B | 228.16B | 2.26% | -2.55% |
| Roche Holding AG (RHHBY) | 228.26B | 263.24B | 2.41% | -2.18% |
| Novartis AG (NVS) | 209.30B | 226.70B | 3.62% | +3.28% |
| Merck & Co., Inc. (MRK) | 250.89B | 274.49B | 3.11% | -9.03% |
| Pfizer Inc. (PFE) | 145.36B | 208.39B | 6.55% | -10.91% |
| Sanofi (SNY) | 121.41B | 139.36B | 4.22% | -2.92% |
| Johnson & Johnson (JNJ) | 373.59B | 389.04B | 3.20% | -1.00% |
| Bristol Myers Squibb (BMY) | 119.40B | 162.48B | 4.08% | +14.73% |
| Eli Lilly (LLY) | 673.53B | 700.77B | 0.70% | +28.32% |
| GlaxoSmithKline (GSK) | 68.52B | 83.90B | 4.58% | -8.36% |
AstraZeneca Balance Sheet Report
AstraZeneca PLC (NASDAQ: AZN) reported a strong balance sheet for the fiscal year ended December 31, 2023. Total assets reached $101.1 billion, up 4.8% from 2022. Liabilities, net of minority interest, amounted to $62.0 billion.
Equity, gross of minority interest, stood at $39.2 billion, a 5.7% increase. Total capitalization reached $61.5 billion, with common stock equity increasing to $39.1 billion.
Capital lease obligations grew to $1.1 billion. Net tangible assets and working capital remained negative at $19.0 billion and $5.5 billion, respectively. Invested capital increased to $66.6 billion.
Total debt slightly decreased to $28.6 billion, while net debt decreased to $21.7 billion. Ordinary shares issued increased to 1,550,162,630, with no preferred shares reported.
Conclusion
From 2025 to 2050, AstraZeneca (AZN) stock price shows potential growth from $90 to $2100, representing a Compound Annual Growth Rate (CAGR) of 13.8%. Our analysis suggests this growth might be driven by innovations in oncology, rare diseases, and artificial intelligence-driven drug development.
FAQs
1. What is the forecast for AstraZeneca stock?
Our analysis projects AstraZeneca stock to grow from $90 in 2025 to $2100 by 2050, with a CAGR of 13.8%. The growth path indicates $210 by 2030, $475 by 2036, $750 by 2040, and $2100 by 2050. Key growth drivers might include oncology innovations, rare disease treatments, and AI-driven drug development platforms.
2. Can AstraZeneca stock reach $100?
Based on our projections, AstraZeneca could reach $100 by 2027, supported by respiratory medicine portfolio expansion and breakthrough developments in Breztri Aerosphere.
3. Can AstraZeneca stock reach $300?
Our analysis suggests AstraZeneca could reach $300 by 2033. This milestone might be achieved through expansion of rare disease treatments like Strensiq and Ultomiris, along with significant market penetration of oncology drugs Calquence and Enhertu.
4. Can AstraZeneca stock reach $500?
The stock could potentially reach $500 by 2037. This growth might be fueled by breakthroughs in precision oncology, expanded indications for Imfinzi, and significant advancements in the immunotherapy segment through Calquence and Enhertu combinations.
5. Can AstraZeneca stock reach $700?
Our analysis indicates AstraZeneca could reach $700 by late 2039. This milestone might be achieved through advancements in personalized medicine, expansion of Orpathys platform, and breakthrough innovations in AI-driven drug development.
6. Is AstraZeneca a “buy”, “hold” or “sell”?
Based on our long-term growth analysis and projected CAGR of 13.8%, AstraZeneca presents as a “buy” opportunity. The company’s strong pipeline in oncology, rare diseases, and cardiovascular medicines, make it a good investment.
Disclaimer:
The stock price predictions provided herein are based on historical data, current market trends, and analysis. However, past performance does not guarantee future results. Stock markets are inherently volatile and subject to numerous economic, political, and market factors that can cause rapid and unpredictable fluctuations in stock prices. The information provided is for educational and informational purposes only and should not be construed as financial advice. It is strongly recommended that you consult with a qualified financial advisor before making any investment decisions. Invest responsibly and consider your individual financial situation, risk tolerance, and investment objectives before acting on any information provided.
